Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by canadapieton Jul 09, 2021 4:46pm
143 Views
Post# 33522695

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Communication manager

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Communication manager 22000 shares, half were mine.......!
No volume for weeks now, with millions of outstanding shares, and a lousy
insider holding and a few "tutes" holding after that horrible oo.......!! 
And they have no risk because of the warrants!

Only "hard" data will change investor sentiment. We can only "hope" data

will be good and we get soon enough informed! 



palinc2000
 - (7/9/2021 4:05:20 PM) 
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Communication manager 

First order of business they should replace the CFO.... Trying to compensate a Cfo 's weakness by hiring LSA is the wrong approach.


quote=scarlet1967]One has to wonder who wants to follow the analysts who are more interested in earning fees than making their clients wealthy. If they just start the coverage based on fees how many promising investment will be left out. Their relevance in today's market with well educated investors is not as it was. That's the reason why the company should directly target their investors, educate them motivate them. Times have changed one either adapt or miss opportunities.

SPCEO1 wrote:Hopefully, if nothing else, they elarned from the mini-revolt that they really don't want to have to spend time on any future such revolts and manage the company in such a way as to avoid them. 

And a decent analyst picking up coverage is massively overdue. I am not sure what will cause that to happen at this point but some strong cancer data would not hurt. New coverage is often associtated with a way in which the borkerage firm can earn fees off a company and if TH ends up gaining cash from partnerships and does not need to do any offerings, that might be an impediment to analysts starting to cover the stock. I trust that LSA and Leah are doing whatever they can to encourage analyst coverage but it probably will not be an easy problem to solve in the short term. We can't even get teh current analysts to effectively cover important developments. Only 2 of the four analysts covering the stock at the moment bothered to write up anything about the cancer webinar. 

qwerty22 wrote:

I'm just looking at how it is.

Change could have just meant the new LSA plan. The plan before the mini investor revolt was LSA. The plan afterwards is LSA, I think they mostly just managed the revolt. Whatever LSA can do for them to get them out of the hole seems to be about it. Although you'd expect other things going on behind the scenes.

A reasonably sized US analyst would do wonders for the mood here.

 

scarlet1967 wrote:

 

The CEO during the chat with concord said they learned from their mistakes and have a plan of action, one has to wonder what mistakes he was referring to?
Surely it can't be the R&D part as that was again during the same they achieving milestones. I believe he was referring to their interactions with the market. Again that can't be the institutional investors as they mostly have been chasing those investors so my take is he was referring to general market retail and institutions. The communication manager among others is supposed to help with presentations so not too fast ruling out a future retail approach.


 

 

<< Previous
Bullboard Posts
Next >>